Kardiorespirator tadqiqotlar jurnali. Maxsus son. 2022
Subject of the article
ВЛИЯНИЕ SARS-CoV-2 НА ТЕЧЕНИЕ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА НА ФОНЕ МЕТАБОЛИЧЕСКОГО СИНДРОМА (4-14)
Authors
Абдиева Г.А., Ташкенбаева Э.Н.
Institution
Самаркандский государственный медицинский университет
Abstract
Пандемия COVID-19 во всем мире развивается в зависимости от сердечно-сосудистых факторов. В данном обзоре описаны последствия COVID-19 для сердечно-сосудистой системы, а также описаны важные международные первичные данные по распространенности сердечно-сосудистой патологии и лечения COVID-19. Гипертоническая болезнь, артериальная гнипертензия, сахарный диабет и сердечно-сосудистые заболевания являясь частыми сопутствующими заболеваниями, связаны с прогрессированием и тяжестью COVID-19. Пациенты, зараженные COVID-19, с многими сопутствующими заболеваниями подвергаются более высокому риску неблагоприятных клинических исходов. Возможно тяжелое течение COVID-19 связана с компонентами метаболического синдрома. В статье приведена возможная связь метаболического синдрома, а также его компонентов с восприимчивостью к инфекции SARS-CoV-2, тяжестью COVID-19 и прогрессированием ишемической болезни сердца (ИБС).
Key words
метаболический синдром, ишемическая болезнь сердца, тяжелый острый респираторный синдром, коронавирусное заболевание (COVID-19), факторы риска.
Literature
1. Cai Q., Chen F., Wang T., Luo F., Liu X., Wu Q., He Q., et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392- 1398. 2. Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13. 3. Engin A.B., Engin E.D., Engin A. Two important contro- versial risk factors in SARS-CoV-2 infection: obesity and smoking. Environ Toxicol Pharmacol. 2020;78:103411. 4. Fatulloyeva D. S. et al. Evaluation of the effectiveness of thrombolytic therapy in myocardial infarction in the conditions of the samarkand branch of rscemc //Euro-Asia Conferences. – 2021. – Т. 1. – №. 1. – С. 177-182. 5. Ghoneim S., Butt M.U., Hamid O., Shah A., Asaad I. The incidence of COVID-19 in patients with metabolic syn- drome and non-alcoholic steatohepatitis: A population- based study. Metabol Open. 2020;8:100057. 6. Grover A., Oberoi M. A systematic review and meta- analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2020. 7. Hariyanto T.I., Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infec- tion. Diabetes Metab Syndr. 2020;14(5):1463-1465. 8. Henry B.M., de Oliveira M.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker ab- normalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-1028. 9. Hidekatsu Yanai Metabolic Syndrome and COVID-19 Cardiol Res. 2020;11(6):360-365 10. Higham A., Singh D. Increased ACE2 Expression in Bron- chial Epithelium of COPD Patients who are Overweight. Obesity (Silver Spring). 2020;28(9):1586-1589. 11. Istamova S.S. et al. Left ventricular diastolic dysfunction in patients with acute myocardial infarction in comorbid condition //Euro-Asia Conferences. – 2021. – Т. 1. – №. 1. – С. 334-338. 12. Kai H., Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648-654.13. Leong A., Cole J., Brenner L.N., Meigs J.B., Florez J.C., Mercader J.M. Cardiometabolic risk factors for COVID-19 susceptibility and severity: a mendelian randomization analysis. medRxiv. 2020. 14. Levi M., Hunt B.J. Thrombosis and coagulopathy in COV- ID-19: An illustrated review. Res Pract Thromb Haemost. 2020;4(5):744-751. 15. Lo K.B., Bhargav R., Salacup G., Pelayo J., Albano J., Mc- Cullough P.A., Rangaswami J. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2020:1-12. 16. Negmatovna T. E., Alievna A. G. Features of ischemic heart disease in association with climacteric cardiopathy //European science review. – 2018. – №. 3-4. 17. Panigada M., Bottino N., Tagliabue P., Grasselli G., Novem- brino C., Chantarangkul V., Pesenti A. et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parame- ters of hemostasis. J Thromb Haemost. 2020;18(7):1738- 1742. 18. Rasuli F. O. et al. Clinical features of ihd course on the background of atrial fibrillation //Euro-Asia Conferences. – 2021. – Т. 1. – №. 1. – С. 195-199. 19. Scalsky R.J., Desai K., Chen Y.J., O'Connell J.R., Perry J.A., Hong C.C. Baseline Cardiometabolic Profiles and SARS- CoV-2 Risk in the UK Biobank. medRxiv. 2020. 20. Tian W., Jiang W., Yao J., Nicholson C.J., Li R.H., Sigurslid H.H., Wooster L. et al. Predictors of mortality in hospital- ized COVID-19 patients: A systematic review and meta- analysis. J Med Virol. 2020. 21. Vaduganathan M., Vardeny O., Michel T., McMurray JJV, Pfeffer M.A., Solomon S.D. Reninangiotensin- aldos- terone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382(17):1653-1659. 22. Varga Z., Flammer A.J., Steiger P., Haberecker M., Ander- matt R., Zinkernagel A.S., Mehra M.R., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417- 1418. 23. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronaviruseinfected pneumonia in Wuhan, China. JAMA 2020;323:1061-9. 24. Yanai H. A significance of high prevalence of diabetes and hypertension in severe COVID-19 patients. J Clin Med Res. 2020;12(6):389-392. 25. Yanai H. Adiposity is the crucial enhancer of COVID-19. Cardiol Res. 2020;11(5):353-354. 26. Yang J., Hu J., Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. J Med Virol. 2020. 27. Zhang J.J., Dong X., Cao Y.Y. et al. Clinical characteristics of 140 patients infected with SARSCoV- 2 in Wuhan, China. Allergy 2020;75: 1730-41. 28. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospec- tive cohort study. Lancet. 2020;395(10229):1054-1062. 29. Zhu J., Pang J., Ji P., Zhong Z., Li H., Li B., Zhang J. Elevat- ed interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2020.